Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

495 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma.
Maeda K, Higashi-Kuwata N, Kinoshita N, Kutsuna S, Tsuchiya K, Hattori SI, Matsuda K, Takamatsu Y, Gatanaga H, Oka S, Sugiyama H, Ohmagari N, Mitsuya H. Maeda K, et al. Among authors: takamatsu y. Sci Rep. 2021 Mar 10;11(1):5563. doi: 10.1038/s41598-021-84733-5. Sci Rep. 2021. PMID: 33692457 Free PMC article.
C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.
Aoki M, Hayashi H, Yedidi RS, Martyr CD, Takamatsu Y, Aoki-Ogata H, Nakamura T, Nakata H, Das D, Yamagata Y, Ghosh AK, Mitsuya H. Aoki M, et al. Among authors: takamatsu y. J Virol. 2015 Nov 18;90(5):2180-94. doi: 10.1128/JVI.01829-15. J Virol. 2015. PMID: 26581995 Free PMC article.
A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency.
Aoki M, Hayashi H, Rao KV, Das D, Higashi-Kuwata N, Bulut H, Aoki-Ogata H, Takamatsu Y, Yedidi RS, Davis DA, Hattori SI, Nishida N, Hasegawa K, Takamune N, Nyalapatla PR, Osswald HL, Jono H, Saito H, Yarchoan R, Misumi S, Ghosh AK, Mitsuya H. Aoki M, et al. Among authors: takamatsu y. Elife. 2017 Oct 17;6:e28020. doi: 10.7554/eLife.28020. Elife. 2017. PMID: 29039736 Free PMC article.
GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.
Delino NS, Aoki M, Hayashi H, Hattori SI, Chang SB, Takamatsu Y, Martyr CD, Das D, Ghosh AK, Mitsuya H. Delino NS, et al. Among authors: takamatsu y. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02060-17. doi: 10.1128/AAC.02060-17. Print 2018 May. Antimicrob Agents Chemother. 2018. PMID: 29463535 Free PMC article.
Novel Protease Inhibitors Containing C-5-Modified bis-Tetrahydrofuranylurethane and Aminobenzothiazole as P2 and P2' Ligands That Exert Potent Antiviral Activity against Highly Multidrug-Resistant HIV-1 with a High Genetic Barrier against the Emergence of Drug Resistance.
Takamatsu Y, Aoki M, Bulut H, Das D, Amano M, Sheri VR, Kovari LC, Hayashi H, Delino NS, Ghosh AK, Mitsuya H. Takamatsu Y, et al. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00372-19. doi: 10.1128/AAC.00372-19. Print 2019 Aug. Antimicrob Agents Chemother. 2019. PMID: 31085520 Free PMC article.
Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies.
Ghosh AK, Xia Z, Kovela S, Robinson WL, Johnson ME, Kneller DW, Wang YF, Aoki M, Takamatsu Y, Weber IT, Mitsuya H. Ghosh AK, et al. Among authors: takamatsu y. ChemMedChem. 2019 Nov 6;14(21):1863-1872. doi: 10.1002/cmdc.201900508. Epub 2019 Oct 4. ChemMedChem. 2019. PMID: 31549492 Free PMC article.
495 results